CO4820391A1 - Compuestos hipolipidemicos de benzotiazepina - Google Patents

Compuestos hipolipidemicos de benzotiazepina

Info

Publication number
CO4820391A1
CO4820391A1 CO99001036A CO99001036A CO4820391A1 CO 4820391 A1 CO4820391 A1 CO 4820391A1 CO 99001036 A CO99001036 A CO 99001036A CO 99001036 A CO99001036 A CO 99001036A CO 4820391 A1 CO4820391 A1 CO 4820391A1
Authority
CO
Colombia
Prior art keywords
benzotiazepine
compound
formula
hypolipidemic compounds
solvate
Prior art date
Application number
CO99001036A
Other languages
English (en)
Inventor
Anthony Louis Handlon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO4820391A1 publication Critical patent/CO4820391A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Un compuesto de la fórmula (I).en dondeR1 es H ó metilo, o una sal, solvato o derivado fisiológicamente funcional del mismo.1Un proceso para la fabricación de un compuesto de la fórmula (I) o una sal, solvato, o derivado fisiológicamente funcional del mismo, que comprende:(A) en donde R1 es H, la desalquilación de un compuesto de la fórmula (II)en donde R1a es una mitad alquilo; ó(B) en donde R1 es un metilo, oxidando un compuesto de la fórmula (III)
CO99001036A 1998-01-10 1999-01-08 Compuestos hipolipidemicos de benzotiazepina CO4820391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9800428.6A GB9800428D0 (en) 1998-01-10 1998-01-10 Chemical compounds

Publications (1)

Publication Number Publication Date
CO4820391A1 true CO4820391A1 (es) 1999-07-28

Family

ID=10825042

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99001036A CO4820391A1 (es) 1998-01-10 1999-01-08 Compuestos hipolipidemicos de benzotiazepina

Country Status (27)

Country Link
US (1) US6465451B1 (es)
EP (1) EP1045840A1 (es)
JP (1) JP2002500220A (es)
KR (1) KR20010033988A (es)
CN (1) CN1292785A (es)
AP (1) AP2000001860A0 (es)
AR (1) AR014261A1 (es)
AU (1) AU2515599A (es)
BR (1) BR9906799A (es)
CA (1) CA2317651A1 (es)
CO (1) CO4820391A1 (es)
EA (1) EA200000623A1 (es)
GB (1) GB9800428D0 (es)
HR (1) HRP20000468A2 (es)
HU (1) HUP0201343A3 (es)
ID (1) ID25495A (es)
IL (1) IL137040A0 (es)
IS (1) IS5551A (es)
MA (1) MA26595A1 (es)
NO (1) NO20003514L (es)
NZ (1) NZ505453A (es)
PE (1) PE20000179A1 (es)
PL (1) PL341672A1 (es)
SK (1) SK10242000A3 (es)
TR (1) TR200001816T2 (es)
WO (1) WO1999035135A1 (es)
ZA (1) ZA9981B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038727A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
SE0000772D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20020183307A1 (en) * 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) * 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
KR100935623B1 (ko) 2001-09-08 2010-01-07 알비레오 에이비 고지혈증 치료를 위한 회장 담즙산 운반(ibat) 억제활성을 가진 벤조티아제핀 및 벤조티아디아제핀 유도체
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
FR2849024B1 (fr) * 2002-12-20 2007-11-02 Aventis Pharma Sa Nouveaux composes chiraux derives d'esters de l'acide hexanoique, procede et intermediaires de preparation, utilisation a la synthese de l'acide 2-(bromomethyl)2-ethyl hexanoique chiral
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
EP2367554A4 (en) 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF OBESITY AND DIABETES
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
RU2619215C2 (ru) 2010-11-08 2017-05-12 Альбирео Аб Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
SI2637668T1 (sl) 2010-11-08 2016-11-30 Albiero Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
DK2771003T3 (en) 2011-10-28 2017-07-17 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease
KR20190135545A (ko) 2011-10-28 2019-12-06 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
MX2015013193A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal.
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
EP3413877B1 (en) 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CR20210027A (es) 2018-06-20 2021-04-29 Albireo Ab Formulación farmacéutica de odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
KR20210126053A (ko) 2019-02-06 2021-10-19 알비레오 에이비 벤조티아디아제핀 화합물 및 담즙산 조절제로서의 그의 용도
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
MX2021009625A (es) 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Métodos para incrementar el crecimiento en sujetos pediátricos que tienen enfermedad de hígado colestásico.
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114761080B (zh) * 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
JP2023504646A (ja) * 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
FI4069360T3 (fi) 2019-12-04 2024-02-20 Albireo Ab Bentsotia(di)atsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004534A1 (en) 1993-08-06 1995-02-16 Smithkline Beecham Corporation Endothelin receptor antagonists
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines

Also Published As

Publication number Publication date
AR014261A1 (es) 2001-02-07
JP2002500220A (ja) 2002-01-08
CN1292785A (zh) 2001-04-25
NO20003514L (no) 2000-09-07
WO1999035135A1 (en) 1999-07-15
NZ505453A (en) 2002-11-26
MA26595A1 (fr) 2004-12-20
AP2000001860A0 (en) 2000-09-30
BR9906799A (pt) 2000-10-10
HRP20000468A2 (en) 2000-10-31
KR20010033988A (ko) 2001-04-25
PL341672A1 (en) 2001-04-23
IS5551A (is) 2000-06-27
AU2515599A (en) 1999-07-26
SK10242000A3 (sk) 2001-02-12
CA2317651A1 (en) 1999-07-15
US6465451B1 (en) 2002-10-15
TR200001816T2 (tr) 2000-11-21
PE20000179A1 (es) 2000-03-16
ZA9981B (en) 2000-07-06
IL137040A0 (en) 2001-06-14
NO20003514D0 (no) 2000-07-07
EA200000623A1 (ru) 2001-04-23
ID25495A (id) 2000-10-05
HUP0201343A2 (hu) 2003-06-28
EP1045840A1 (en) 2000-10-25
HUP0201343A3 (en) 2003-08-28
GB9800428D0 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
CO4820391A1 (es) Compuestos hipolipidemicos de benzotiazepina
BRPI9917739B8 (pt) composto intermediário na preparação de inibidores de cox-2
ES2182234T3 (es) Inhibidores de metaloproteasa.
CY1107403T1 (el) Μια μεθοδος δια την παρασκευη υπερινδοπριλης,των αναλογων ενωσεων αυτης και των αλατων αυτων με χρησιμοποιηση ενδιαμεσων ενωσεων 2,5-διοξο-οξαζολιδινης
ATE236154T1 (de) Pyrrolydin-derivate mit einer phospholipase a2 inhibierenden wirkung
EA200000358A1 (ru) Способ получения диарилпиридинов, полезных в качестве ингибиторов cox-2
NO20014925L (no) Farmasöytiske forbindelser
PT902022E (pt) Novos derivados de benzofuranona e processo para a sua producao
ES2151977T3 (es) Inhibidores de accion doble que contienen 1,2-diazepina.
AR006058A1 (es) Procedimientos para preparar compuestos de dicianoacetato y de 1,2-pirazol-5-amino-3-substituido
ATE195513T1 (de) 22-thiavitamin-d3-derivate
FI955498A (fi) Nipekotiinihappojohdannaisia hyytymistä estävinä aineina
ATE233264T1 (de) Polynalbuphinderivat
UY26388A1 (es) Procedimiento para la preparacion de compuestos de pirazolo (4,3-d) pirimidin - 7-onas-3- piridilsulfonilo e intermedios de los mismos.
PT1105392E (pt) Processo para a preparacao de intermediarios de imidazodiazepina
ES2195500T3 (es) Dereivados del 2-indanometanol y su utilizacion a titulo de ingredientes perfumantes.
PT98268A (pt) Processo para a preparacao de indano-pirrolidino-carbamatos
ATE308499T1 (de) Verfahren zur herstellung von anthracyclinederivaten
BR9907340A (pt) Ciclo-heptenos substituìdos, e processo para a produção de um composto
PT842924E (pt) Intermediarios de piridina uteis na sintese de agonistas de receptores beta-adrenergicos
EA200001212A1 (ru) Усовершенствованный способ получения производных норбензоморфана с ценными фармацевтическими свойствами
ES2194361T3 (es) Procedimiento y compuestos intermedios para la preparacion de un herbicida de triazol.
DE69004320D1 (de) Hydroxyphenethylamin-Derivat und dessen Salze, Verfahren zur Herstellung, medizinische Verwendung und Verwendung als spezifisches pharmakologisches Werkzeug.
BR0117362B1 (pt) processo para a preparação de um composto derivado de 2-piridilmetilamina de fórmula geral (v)
BR8900601A (pt) Processo para a preparacao de compostos de 1,2-dissulfona